A decade after its launch, the effort has detected almost 18,000 human proteins and is shifting its focus more on different protein forms and functional data.
The tests are designed to detect viral nucleic acid in various respiratory specimens including nasal swabs, nasal aspirate, and bronchoalveolar lavage.
Investigators identified disease-associated histone modifications in the brain that appeared to influence transcription- and chromatin-related processes.
Investors included Bruker, whose MALDI mass spectrometry imaging platforms could have synergies with Ionpath's Multiplexed Ion Beam Imaging technology.
Instead of measuring metabolites directly, the researchers used mass cytometry and multiplexed ion beam imaging to measure proteins involved in metabolic regulation.
Working with ETH Zurich researchers, the firm has incorporated machine learning to improve the platform's performance in complex organisms like humans.
The firm said it plans to use the proceeds to support the launch of its first product based on its structures for lossless ion manipulation ion mobility system.
Recently developed deep learning tools and other software packages have streamlined DIA mass spec workflows and are driving uptake within proteomics cores.
The pair are working on reagents and mass spec approaches to improve isolation and analysis of crosslinked peptides for protein interaction and structural studies.
The Singapore-based company will use the funds to expand its presence in the US and develop its platform, which uses mass cytometry to profile T-cell response.
